Michele P Andrasik
Overview
Explore the profile of Michele P Andrasik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1583
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Theodore D, Neradilek M, Gillespie K, Edupuganti S, Hinojosa J, Lama J, et al.
J Acquir Immune Defic Syndr
. 2025 Feb;
98(4):340-345.
PMID: 39970314
Background: Realizing the potential of HIV prevention options requires understanding product tolerability across diverse groups vulnerable to HIV acquisition. Gender minority (GM) individuals are understudied in clinical trials. Setting: HVTN...
2.
Carpp L, Hyrien O, Fong Y, Benkeser D, Roels S, Stieh D, et al.
Nat Commun
. 2024 Nov;
15(1):9785.
PMID: 39532861
Assessment of immune correlates of severe COVID-19 has been hampered by the low numbers of severe cases in COVID-19 vaccine efficacy (VE) trials. We assess neutralizing and binding antibody levels...
3.
Zhang B, Fong Y, Fintzi J, Chu E, Janes H, Kenny A, et al.
Nat Commun
. 2024 Sep;
15(1):7954.
PMID: 39261482
In the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be correlates of risk (CoR) and of protection...
4.
Huang Y, Hejazi N, Blette B, Carpp L, Benkeser D, Montefiori D, et al.
Viruses
. 2023 Oct;
15(10).
PMID: 37896806
The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding antibodies (bAbs), anti-receptor binding domain...
5.
Benkeser D, Montefiori D, McDermott A, Fong Y, Janes H, Deng W, et al.
Sci Transl Med
. 2023 Apr;
15(692):eade9078.
PMID: 37075127
The best assay or marker to define mRNA-1273 vaccine-induced antibodies as a correlate of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA-1273 COVID-19...
6.
Fong Y, Huang Y, Benkeser D, Carpp L, Anez G, Woo W, et al.
Nat Commun
. 2023 Mar;
14(1):1581.
PMID: 36949083
No abstract available.
7.
Malahleha M, Laher F, Dilraj A, Smith P, Gray G, Grove D, et al.
AIDS Behav
. 2023 Mar;
27(9):3027-3037.
PMID: 36929319
In South Africa, HIV acquisition risk has been studied less in people assigned male at birth. We studied the associations between risk behaviors, clinical features and HIV incidence amongst males...
8.
Benkeser D, Fong Y, Janes H, Kelly E, Hirsch I, Sproule S, et al.
NPJ Vaccines
. 2023 Mar;
8(1):36.
PMID: 36899062
In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the U.S., Chile, and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% neutralizing antibody titer...
9.
Fong Y, Huang Y, Benkeser D, Carpp L, Anez G, Woo W, et al.
Nat Commun
. 2023 Jan;
14(1):331.
PMID: 36658109
In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and pseudovirus 50% neutralizing antibody titer (nAb...
10.
Jaramillo J, Pagkas-Bather J, Waters K, Shackelford L, Campbell R, Henry J, et al.
Sex Res Social Policy
. 2022 Nov;
19(3):1058-1068.
PMID: 36387840
Introduction: HIV PrEP (pre-exposure prophylaxis) is underutilized among Latinx and Black men who have sex with men (MSM) in the United States. Although peer navigation approaches may increase PrEP uptake...